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We examined survival in screened-detected and non-screen-detected women diagnosed in the West Midlands (UK) and New
South Wales (Australia) in order to evaluate whether international differences in survival are related to early diagnosis, or to
other factors relating to the healthcare women receive. Data for women aged 50265 years who had been eligible for screen-
ing from 50 years were examined. Data for 5,628 women in West Midlands and 6,396 women in New South Wales were linked
to screening service records (mean age at diagnosis 53.7 years). We estimated net survival and modelled the excess hazard
ratio of breast cancer death by screening status. Survival was lower for women in the West Midlands than in New South Wales
(5-year net survival 90.9% [95% CI 89.9%291.7%] compared with 93.4% [95% CI 92.6%-94.1%], respectively). The difference
was greater between the two populations of non-screen-detected women (4.9%) compared to between screen-detected
women, (1.8% after adjustment for lead-time and over-diagnosis). The adjusted excess hazard ratio of breast cancer death for
West Midlands compared with New South Wales was greater in the non-screen-detected group (EHR 2.00, 95% CI 1.7022.31)
but not significantly different to that for women whose cancer had been screen-detected (EHR 1.72, 95% CI 0.8722.56). In
this study more than one in three breast cancer deaths in the West Midlands would have been avoided if survival had been
the same as in New South Wales. The possibility that women in the UK receive poorer treatment is an important potential
explanation which should be examined with care.
We have previously shown a difference of 6% in 5-year breast
cancer survival between Australia and England for women in
the target age group for screening and diagnosed during the
period 19962 1999.1 Examining survival by screening status
has the potential to shed further light on whether international
differences are more likely to be due to tumour or patient fac-
tors or to other factors relating to the healthcare women
receive. We have previously identiﬁed these as possible explan-
ations for socioeconomic differences,2 but they also may
explain international variations in survival.1
The trials that led to the implementation of mammo-
graphic screening worldwide were evaluated by examining
the reduction in breast cancer mortality amongst the popula-
tions of women screened.3 In this context, a reduction in the
number of breast cancer deaths in the screened population
can be interpreted as the number of cancer deaths avoided or
deferred by the intervention. This outcome is helpful in eval-
uating the public health impact and economic value of the
screening programme as a whole.
Other studies have examined the impact of mammo-
graphic screening upon individual patient survival. Analyses
of survival include examinations of interval cancers4,5 (can-
cers diagnosed following a normal mammogram but prior to
the next screening invitation), comparisons of women in
dichotomous groups (attenders vs. never-attenders6 and those
with screen-detected vs. non-screen-detected cancers7) and
spatial analyses.8 A review conducted in the UK in 20039
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concluded that a better understanding of the effect of screen-
detection required more detailed data. In particular, the
review identiﬁed the importance of linkage of mortality data
to screening invitations so that the outcome for tumours
diagnosed after the introduction of screening might be
examined.
Examination of survival by screening status enables us to
establish, at the population level, the survival beneﬁt afforded
to women whose cancers were screen-detected compared to
women whose cancers were detected symptomatically. The
disadvantage of this approach is that it is susceptible to lead-
time bias and to over-diagnosis. Lead-time is the additional
observation time credited to women who are screen-detected
by virtue of the fact that they are asymptomatic. Breast
tumours considered to be “over-diagnosed” are those detected
by screening mammography but which would not have been
diagnosed during the patient’s lifetime in the absence of
screening.10 These biases together lead to apparently better
survival, even if the actual time of death is not deferred. This
skews estimates of survival in favour of screening, resulting
in statistics which appear to show a survival advantage
amongst women who have been screened, even when none
might exist. Recently, methodological advances have been
made into ways to account for lead-time bias in the analysis
of survival so that the underlying differences in survival can
be assessed. This involves correcting the observed survival
time to account for the additional follow-up observed in the
cohort as a result of screen-detection.11
In this article, we examine net survival for breast cancer in
screen-detected and non-screen-detected women diagnosed in
the West Midlands (UK) and New South Wales (Australia),
applying a correction for lead-time bias and over-diagnosis. We
use the results to discuss the extent to which the international
differences in breast cancer survival between the UK and Aus-
tralia may be explained by tumour or patient factors or to other
factors relating to the healthcare women receive.
Materials
The cohort of interest consisted of women who were invited
to attend for screening mammography in a fully-functioning,
mature screening programme during a deﬁned calendar
period. Women diagnosed with a primary invasive breast
cancer at ages 50–65 years during the period 1 January 1997
to 31 December 2006 and aged 51 years or younger on 1 Jan-
uary 1997 were considered eligible (Fig. 1). We thus excluded
women who were ﬁrst invited to be screened at ages over 50
years, as well as women invited during the years when the
screening programme was being established and expanded.
We excluded women aged over 65 years at diagnosis because
the target age for screening was up to age 64 years in the UK
during this period. The eligibility criteria resulted in a cohort
which built up over time (median month of diagnosis August
2003 in West Midlands and November 2003 in New South
Wales). All women were followed up to 31 December 2008
(at least 2 years following diagnosis). Data were obtained
from the West Midlands Ofﬁce of the English National Can-
cer Registration Service (WMNCRS, England) and the New
South Wales Central Cancer Registry (NSWCCR, Australia).
These two registries cover populations of 5.6 and 6.9 million,
respectively.12,13
Information was obtained from each cancer registry on
each woman’s age at diagnosis (completed years), the month
and year of their diagnosis and death (if dead), the sub-site,
grade, histology and behaviour of the tumour, and all infor-
mation pertaining to the extent of disease at diagnosis
(stage). Staging information for cases in the West Midlands
was recoded according to the rules used by the New South
Wales Central Cancer Registry: localised (conﬁned to the
organ of origin), regional (spread to adjacent muscle, organ,
fat, connective tissue or regional lymph nodes), distant (dis-
tant metastasis) and unknown stage.
The cancer registry data were linked to the population-
based mammographic screening service records in each local-
ity to establish each woman’s screening status at diagnosis (the
National Health Service Breast Screening Programme for the
West Midlands and BreastScreen NSW for New South Wales).
We deﬁned four categories for the screening status at diagno-
sis: (1) women whose cancer was detected at a routine screen,
(2) women who presented with cancer following a negative
screen but before being invited to their next routine screen
(interval cancers), (3) women who presented with cancer after
at least one negative screen but who had not attended their
most recent appointment (lapsed attenders), and (4) women
who presented with cancer who had never attended screening.
We also compared women in the screen-detected group (Cate-
gory 1) to all those with non-screen-detected cancer (Catego-
ries 2, 3 and 4). This broadly corresponded to comparing
those with asymptomatic disease identiﬁed via routine screen-
ing to women presenting with symptomatic disease.
Methods
Net survival estimation
Net survival is deﬁned as the survival from the disease of
interest. It is derived by adjusting the overall survival in the
What’s new?
Breast cancer patients in Australia are known to have higher survival than those in the UK. In this study, the authors found
that these international differences in survival persist in both screen-detected and non-screen-detected groups, even after
adjustment for both lead-time bias and over-diagnosis. These results suggest that it is essential that the mechanisms underly-
ing these differences be understood, including potential variations in effective treatment between the two regions.
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patient group for their expected survival in the absence of
the disease. We estimated net survival using the non-
parametric Pohar-Perme estimator,14 which has been imple-
mented in Stata.15 The Pohar-Perme estimator is an unbiased
estimator of net survival with respect to informative censor-
ing (deﬁned as the tendency for the estimates to reﬂect the
survival of patients with lowest expected mortality as time
since diagnosis increases) for population-based data.16,17
We estimated expected survival from region-speciﬁc life
tables provided by the Ofﬁce for National Statistics for Eng-
land and Wales and the Australian Bureau of Statistics1 for
each calendar year of follow-up.
Adjustment for lead-time and over-diagnosis
To account for the potential effect of lead-time bias, we cal-
culated additional survival time due to screening, E(s), for
the screen-detected group, as proposed by Duffy et al.11 and
assuming a mean sojourn time (time from carcinogenesis to
symptomatic cancer in the absence of screening) in both
regions of 4 years. We applied 10 separate simulations to
obtain a range of possible values, E(s)1, E(s)2 . . . E(s)10, by
assuming that survival times were exponentially distributed
with a mean of E(s). Values of E(s) were subtracted from
observed survival time in order to obtain corrected survival
time (Fig. 2, Patients A and B).
We considered tumours to be over-diagnosed if they
would not have been detected symptomatically during the
study period or during the predicted lifetime of the patient.
To account for over-diagnosis we excluded tumours in
instances where the value of E(s)1, E(s)2 . . . E(s)10 exceeded
the woman’s actual observed survival time, either because the
predicted date of diagnosis was after 31st December 2008, or
before her death. (Fig. 2, Patients C and D).
We used the corrected survival times to estimate non-
parametric net survival for each of these ten separate data
sets for the screen-detected group. We used the rules estab-
lished by Rubin18 for the re-combination of estimates in a
multiple-imputation setting to derive an overall estimate of
net survival and its variance, adjusted for lead-time bias and
over-diagnosis (Fig. 3a).
Missing data
Data on extent of disease were missing for 8.9% of women
diagnosed in West Midlands and 5.3% of those diagnosed in
New South Wales. We used a 10-fold hot-deck approach to
take account of these missing values for extent of disease.
Figure 1. (a) Schematic diagram of women eligible for the study alongside (b) a histogram showing the total number of women included in
New South Wales (Australia) and the West Midlands (UK) by year of diagnosis (1997–2006).
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The hot-deck approach involves identifying ‘donor groups’
for each woman with missing information on extent of dis-
ease. The donor group for each woman comprised women
diagnosed in the same period (1997–2000, 2001–2006) and
region (West Midlands, New South Wales), at a similar age
(2 groups: 50–53 years [prevalent screening round], 541
years [incident screening rounds]) who had been followed for
a similar amount of time (6 groups: up to 1 year, 1-1.9 years,
2-3.9 years, 4-5.9 years, 6-7.9 years and 81 years), and with
the same vital status at the end of follow-up (dead, alive),
and screening status (screen-detected, not screen-detected).
For each woman with missing data, ten separate values of
extent of disease (extent1, extent2 . . . extent10) were obtained
by randomly and independently selecting values of extent of
disease from the donor group.
Combining these two procedures resulted in data sets with
a set of 10 imputed values for the variable extentj for both
the screen-detected group and non-screen-detected group,
and a set of 10 imputed values for the variable E(s)i for the
screen-detected only (where i5 1–10).
Modelling
We ﬁtted ﬂexible non-parametric regression models for net
survival19 to estimate the excess hazard ratio associated with
being diagnosed with breast cancer in the West Midlands
compared to New South Wales. We ﬁtted 10 models for
women with screen-detected cancer using the values E(s)1 to
E(s)10 combined with extent1 and one model for the non-
screen-detected cancer using observed survival times and val-
ues of extent1. A priori, we included age at diagnosis, region
and extent of disease in the models. We used a reduction of
3 or more in the AIC (Akaike Information Criterion) to
indicate a better ﬁt. We examined non-linearity of age by the
inclusion of restricted cubic splines and tested for time-
varying effects for region, age at diagnosis, and extent of dis-
ease. We examined interactions between region and age, and
between region and extent of disease.
For the screen-detected group, we applied the model with
the smallest number of parameters to each unique combina-
tion of E(s)i and extentj (100 separate combinations of
results). For non-screen-detected women we reﬁtted the
model found to ﬁt best to using values of extent1 to the data
for extent2, extent3 . . . extent10 (10 sets of results).
We predicted from the ﬁnal models estimates of crude
mortality20 due to breast cancer and crude mortality due to
other causes for the whole cohort. Crude mortality can be
derived directly from the net survival models,21 and allows
the mortality observed during follow-up to be partitioned
into mortality due to the cancer itself and due to other
causes. Estimates of crude mortality were derived for each of
the covariate patterns in the sample and a weighted average
of deaths due to breast cancer across all patterns was calcu-
lated by region and screening. Estimates were derived sepa-
rately for screen-detected women and non-screen-detected
women in West Midlands and New South Wales.
We used Rubin’s rules18 to re-combine the 100 separate
estimates of the excess hazard ratio of breast cancer death
and crude mortality from breast cancer for screen-detected
women and the 10 separate estimates for non-screen-detected
women. This resulted in separate estimates for screen-
detected and non-screen-detected women of the relative
change in the excess hazard of death due to breast cancer for
women living in West Midlands compared to women in New
South Wales, as well as the crude probability of death from
Figure 2. Schematic diagram demonstrating the exclusion of women in order to adjust for lead-time bias and over-diagnosis.
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breast cancer and other causes, and their associated variances.
These ﬁnal estimates took into account lead-time bias and
over-diagnosis in the screen-detected group and were also
adjusted for age and extent of disease at diagnosis (Fig. 3b).
The estimates of crude mortality were used to establish
the number of cancer deaths that could have been avoided in
the hypothetical situation in which survival was equalised
between the two regions. This provides an estimate of the
public health impact of survival differentials22 in the net sur-
vival setting.
Results
We analysed data for 5,628 women in West Midlands (98.5%
of those eligible, mean age at diagnosis 53.7 years) and 6,396
women in New South Wales (99.9% of those eligible, mean
age at diagnosis 53.8 years). Those excluded were the very
small number of women who were known to the registry
only because breast cancer had been mentioned on their
death certiﬁcate (DCOs) or because the sequence of dates
provided was illogical. The proportion of tumours that were
screen-detected was greater in West Midlands (44.8% com-
pared to 36.5%, Table 1). The majority of women were diag-
nosed with localised disease, (54.1% in West Midlands, 53.9%
in New South Wales). Fewer than one in ten women died
during follow-up: 10.8% in West Midlands and 7.6% in New
South Wales.
Overall, net survival in the cohort was high (Table 1).
Consistent with our previous ﬁndings,1 net survival overall
was signiﬁcantly lower in the West Midlands than in New
South Wales (5-year net survival 90.9% [95% CI
89.9%291.7%] and 93.4% [95% CI 92.6%294.1%], respec-
tively). Women diagnosed with interval cancers in New
South Wales had lower survival than screen-detected women
(5-year net survival 93.5% compared to 98.5%), but better
survival than women who had never attended screening
(89.5%) and those who had attended previously but lapsed in
attendance prior to diagnosis (86.8%; Table 1, Fig. 4a). In
West Midlands, however, the survival of women diagnosed
with interval cancers was not dissimilar to that of lapsed
attenders, whilst those who had never attended had the worst
survival (Table 1, Fig. 4b). The difference in net survival
between West Midlands and New South Wales was greater
among non-screen-detected women (4.9% ﬁve years after
diagnosis) than among screen-detected women in the two
regions (1.8%; 1.0% before adjustment for lead-time bias,
Table 1).
Figure 3. Schematic diagram illustrating (a) net survival estimation correcting for lead-time bias and over-diagnosis and (b) the modelling
strategy taking into account missing values for extent of disease.
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The ﬁnal models were adjusted for age and extent of dis-
ease at diagnosis. For screen-detected women all effects
(excess hazard ratios of breast cancer death) were constant
over follow-up time and followed a log-linear form. The
effect of age upon survival amongst non-screen-detected
women was non-linear. The effect of both age and extent of
disease were found to change over follow-up time amongst
non-screen-detected women. The excess hazard of death
from breast cancer within ﬁve years of diagnosis in the base-
line model was 57% higher among women diagnosed in the
West Midlands than women in New South Wales (95% CI
35%-80%, Table 2). The baseline (age-adjusted) disadvantage
was slightly greater for women with non-screen-detected can-
cer (EHR 1.65, 95% CI 1.402 1.89) than for women whose
cancer had been screen-detected (EHR: 1.46, 95% CI
0.732 2.20). After additional adjustment for extent of disease
these differentials increased (EHR 2.00, 95% CI 1.70-2.31 in
the non-screen-detected and 1.72, 95% CI 0.872 2.56 for
screen-detected cancer).
Crude mortality due to breast cancer 5 years after diagno-
sis was correspondingly much higher in the West Midlands.
Amongst the cohort of women we examined, an estimated
total of 236 deaths, 38.1% of those due to breast cancer,
would have been avoided in the West Midlands had their
survival been the same as those diagnosed in New South
Wales; 200 (40.2%) amongst non-screen-detected women and
36 (29.5%) amongst those whose cancer was screen-detected
(Table 2).
Discussion
Breast cancer survival for the women included in this study was
signiﬁcantly lower in West Midlands (UK) than New South
Wales (Australia), which is fully consistent with our previous
ﬁndings.1,23–27 Our results further show the extent and persist-
ence of this difference amongst a cohort of peri-menopausal
women who were invited for screening in a mature, fully func-
tioning population-based screening programme.
Survival differences
In the West Midlands, 5-year survival amongst women who
had never attended for screening was 4.9% lower (absolute
difference) than amongst the never-attenders in New South
Figure 4. Net survival estimates for women aged 50–65 (mean age 53.7 years) diagnosed with breast cancer 1 January 1997–31 December
2006 and followed up to 31 December 2008. (a) by screening status, New South Wales, (b) by screening status, West Midlands, (c) screen-
detected compared to non-screen-detected, New South Wales, (d) screen-detected compared to non-screen-detected, West Midlands.
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Wales. For women whose cancer was screen-detected, this
difference was 1.7% after adjustment for lead-time bias.
The 5-year adjusted excess hazard ratio of breast cancer
death for the non-screened group indicates a substantial and
signiﬁcant survival disadvantage for West Midlands. This is
striking because these estimates are adjusted for differences
in age and extent of disease at diagnosis, and so one might
expect survival to be much more similar. Even among
screen-detected women the survival disadvantage is distinct
which is particularly striking because these are women diag-
nosed with asymptomatic cancers. Their tumours are pre-
dominantly localised, and as such they would almost all be
treated surgically and with curative intent and have a high
chance of long-term survival.
Although the overall number of deaths is relatively modest
in this cohort of cancer patients, with only 9.1% of all
women dying during follow-up, the impact of these differen-
ces is important. The increased excess hazard of breast cancer
death 5 years after diagnosis in the West Midlands is double
that of New South Wales amongst non-screen-detected
women and 72% greater amongst those with a screen-
detected cancer. Overall we estimated that more than a third
of the deaths attributable to breast cancer observed for
women in West Midlands would have been avoided had their
survival been the same as the women in New South Wales.
Bias and artefact
Taken together, our results suggest that differences in screen-
ing practice and extent of disease at diagnosis do not explain
the overall difference in survival between West Midlands and
New South Wales for this age group, and that women with
breast cancer in West Midlands have a higher risk of excess
death from their cancer than women in New South Wales,
whether they are screened or not.
The role of ‘de facto’ screening
These differences in survival are likely to be in part due to
the differences in the way screening is delivered in the West
Midlands and in New South Wales. In the UK, the National
Health Service is free at the point of delivery for the whole
population and private mammography is rare. In contrast, in
Australia, mammography is obtained through BreastScreen
Australia but also through private radiology clinics. Mammo-
grams conducted privately for diagnostic purposes, rather
than in asymptomatic women, may be refunded via the Med-
icare Beneﬁts Scheme (MBS). A substantial proportion of
Table 2. Numbers of deaths, excess hazard ratios of breast cancer death and estimates of avoidable mortality within five years of diagnosis:
women aged 50–65 (mean age 53.7 years) diagnosed with invasive breast cancer 1 January 1997–31 December 2006 and followed up to 31
December 2008 in New South Wales (Australia) and the West Midlands (UK)
Non-screen-detected Screen-detected
New South
Wales
West
Midlands
New South
Wales
West
Midlands
Number of women
Total T 4,061 (100.0) 3,104 (100.0) 2,335 (100.0) 2,524 (100.0)
Excluded when correcting for
lead-time and over-diagnosis
E N/A N/A 945 (40.5) 990 (39.2)
Included in analyses I5 T – E 4,061 (100.0) 3,104 (100.0) 1,390 (59.5) 1,534 (60.8)
Excess Hazard Ratios (EHR)
Overall EHR, adjusted
only for age (95% CI) [NSW reference]
1.57 (1.35-1.80)
Baseline EHR, adjusted only
for age (95% CI)
1.00 1.65 (1.40-1.89) 1.00 1.46 (0.73-2.20)
Screening-specific EHR,
adjusted (95% CI)
1.00 2.00 (1.70-2.31) 1.00 1.72 (0.87-2.56)
Avoidable mortality 5 years after diagnosis
Crude mortality due to breast cancer (%) CM 9.5 16.0 5.6 7.9
Corresponding number of deaths due
to breast cancer
Dactual5 I * CM 388 496 77 121
If excess hazard of death due to breast cancer in West Midlands was equal to New South Wales
Deaths due to breast cancer Dequal5 IWM * CMNSW N/A 296 N/A 85
Deaths due to breast cancer that
could be avoided (% of deaths
due to breast cancer)
Davoid5Dactual2Dequal N/A 200 (40.2) N/A 36 (29.5)
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those conducted in private clinics is likely to constitute de
facto screening, (regular diagnostic mammography not
recorded by BreastScreen Australia), but it is unknown to
what degree this occurs.28 This is likely to be the reason for
the higher proportion of tumours in the West Midlands that
were apparently screen-detected, despite a shorter screening
interval in New South Wales. It also implies that women in
New South Wales whom we deﬁned as ‘never-attenders’
includes a sub-group of women who had, in fact, been
screened outside of the national screening programme. This
interpretation is supported by the observation that a signiﬁ-
cantly larger proportion of these women classiﬁed as ‘never-
attenders’ in New South Wales were diagnosed with localised
tumours (50.8% compared to 46.6% in West Midlands).
Although it is probable that we incorrectly allocated some
women to the never-attender group who were actually screen-
detected, especially in New South Wales, information on their
personal characteristics and the features of their cancer would
not have been compromised since these data items were col-
lected from the Cancer Registry, rather than via the screening
service. It is possible, however, that this may have biased our
estimates of net survival. We therefore performed a sensitivity
analysis to examine the potential for de facto screening to
explain the difference in survival for the non-screen-detected
group. We randomly reallocated women in New South Wales
with localised disease from the non-screen-detected to the
screen-detected group, for selected proportions ranging from
1% to 95%, and then re-estimated the net survival function.
Over 100 iterations the ﬁve-year net survival estimates for the
non-screen-detected group in New South Wales became simi-
lar to those for West Midlands only when an implausible 90%
of the localised cancers (43% of all non-screen-detected can-
cers, c. 1800 women) were reallocated (data not shown). This
level of reallocation would require that the true proportion of
cancers screen-detected in New South Wales in the cohort
was in excess of 64%, in comparison to the 36.5% actually
observed (and the 44.8% observed in West Midlands, that
probably reﬂects the order of magnitude one might expect for
New South Wales, since private mammography is very rare in
West Midlands). For smaller, but substantial proportions of
reallocation the reduction in the survival difference was rela-
tively small. We thus consider it very unlikely that de facto
screening can fully explain the difference in survival between
non-screen-detected women. This analysis also served to illus-
trate the robust nature of the difference for the screen-
detected group: there remained a survival advantage for New
South Wales, albeit very small, even when 95% of localised
(apparently symptomatic) tumours were reallocated to the
screen-detected group.
Screening-specific biases
We may consider whether the longer screening interval in
the West Midlands compared with New South Wales (3 years
versus 2 years) might contribute to these differences. Screen-
detected cancers in New South Wales could perhaps be
diagnosed at an earlier stage, with better prognosis. However,
the distribution by extent of disease was similar in both
regions; the proportion of localised disease was in fact slightly
higher in the West Midlands than in New South Wales
(67.1% versus 64.1%, Table 1). A shorter screening interval
will lead to detection of a greater number of slower-growing
tumours, but also greater numbers of aggressive, faster-
growing tumours, which will also be identiﬁed at an earlier
stage than would otherwise be the case. In our data, the dis-
tribution of tumours by extent of disease amongst interval
cancers was fairly similar in both regions (localised tumours
representing 51.8% in New South Wales and 50.0% in West
Midlands, Chi2 p value 0.07) This supports the interpretation
that the breast cancer survival differences between New South
Wales and West Midlands cannot be fully explained by the
shorter screening interval in New South Wales.
We have made adjustment for lead-time and over-
diagnosis in our analysis, and demonstrated that the survival
differences observed are robust to these biases. Adjustment
involved a ten-fold simulation where both the individual sur-
vival times were shortened and the number of women
included in the cohort was reduced. On average, the survival
time of screen-detected women was reduced by 1.5 years and
40% were excluded (Table 2). This latter proportion does not
represent the percentage of tumours over-diagnosed, but
rather the probability that a screen-detected cancer would
not have been detected symptomatically during the period of
time between the actual date of diagnosis and 31st December
2006 (the mean of which was 3.4 years). The number of
tumours over-diagnosed might be reasonably obtained by
estimating the probability that the cancer would not have
been detected symptomatically during the woman’s remain-
ing expected life time (the mean of which was 30.6 years).
Other non-causal explanations
We have previously summarised the possible non-causal
explanations for this difference.1 The ﬁrst of these that may
be applicable here is the possibility that the NSWCCR Regis-
try more often fails to link a woman’s death to the record of
her cancer registration than the WMNCRS, leading to appa-
rently inﬂated survival. This explanation is very unlikely to
apply in this younger age group during this period of time –
these are young women among whom death is a relatively
rare event, and who were followed up during a period of reli-
able death registration. The second possible explanation is
that a higher proportion of in situ tumours registered in New
South Wales were misclassiﬁed as invasive breast cancers
than in the West Midlands. Again, we do not consider that
this could be an explanation for the differences observed in
this study, since >99% of the tumours analysed were micro-
scopically veriﬁed and in situ cancers were excluded. We
have also previously considered the accuracy and consistency
of date of diagnosis as a potential mechanism by which sur-
vival in New South Wales might be extended relative to West
Midlands. Again, however, this explanation has very little
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credibility here, since the date of diagnosis is established in
the same manner for both screen-detected and non-screen-
detected women.
Potential Explanations
Examining possible explanations operating before diagnosis,
the differences in breast cancer survival between West Mid-
lands and New South Wales could arise from (a) greater
delays in diagnosis in West Midlands, (b) longer waiting
times for hospital consultation for non-screen-detected can-
cers or (c) less effective screening in West Midlands than in
New South Wales. The fact that differences persist after
adjustment for extent of disease at diagnosis does not support
any of these explanations, however. It is theoretically possible
that residual confounding may partially account for this lack
of explanatory power. Residual confounding may have arisen
due to the fact that the screening interval for women in West
Midlands is longer than in New South Wales, combined with
a tendency for the accuracy of the ‘extent of disease’ variable
for non-screen-detected cancers to be lower in West Mid-
lands. Together, this would imply that within each stage
grouping, the true (unknown) stage of disease is more
advanced in West Midlands than in New South Wales (stage
migration).29 This would have the effect of better extent-
adjusted survival in New South Wales. Although this expla-
nation is possible, we consider that in the context of this
study it is not very likely. This is because two mechanisms
would both need to apply: delays for non-screen-detected
cancers matched with less effective screening for screen-
detected cancers leading to differences in extent of a similar
magnitude in both groups. At the very least, the fact that
there is a signiﬁcant difference in survival amongst women
with screen-detected disease in the two regions refutes the
hypothesis that international differences are entirely due to
practitioner delay in referral (since all these women were
diagnosed through routine screening) or differences in
patient delay in seeking medical diagnosis following the
detection of breast cancer symptoms.
These ﬁndings thus tend to refute the idea that breast
cancers in West Midlands and New South Wales are very
different at the point of diagnosis, but are subsequently
treated with similar effectiveness. We consider a much more
likely explanation for our ﬁndings is that the tumours them-
selves are not substantially different, but that something dif-
ferent happens once the woman is diagnosed. This is of
greater concern: we have examined a group of young women
with predominantly localised disease. Almost all of them
would have had treatment with curative intent.
Treatment may vary with comorbidity, and is subject to
patient compliance, but there is no particular reason to
assume that these would persistently differ between New
South Wales and West Midlands, particularly in this age
group. The alternative explanation is that the treatment in
West Midlands is not as effective as those in New South
Wales leading to poorer stage-speciﬁc survival.24
Conclusions
Although overall survival was high for this cohort of women,
our data suggest that more than one in three breast cancer
deaths within ﬁve years of diagnosis in the West Midlands
would be avoidable if ﬁve-year survival were the same as in
New South Wales. The women we analysed here are rela-
tively young. They are therefore less likely to be suffering
from other serious illnesses and more likely to be economi-
cally and socially active. In order to improve the prognosis
for women diagnosed with breast cancer in the UK during
their early 50s it is essential that we understand better the
mechanisms that underlie these international differences in
stage-adjusted survival. Differences in the effectiveness of
treatment are an important possibility and they now deserve
to be examined with great care. It is not possible to dismiss
differences in breast cancer survival between the UK and
other countries such as Australia as artefactual.
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